Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04725188
Title Vibostolimab (+) Pembrolizumab Coformulation (MK-7684A) or Vibostolimab (+) Pembrolizumab Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Docetaxel + MK-7684A

MK-7684A

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST